Diet influences survival after stage 3 colon cancer, Dana-Farber study finds

The Directors: Mary Beckerle and Neli Ulrich on delivering cancer care across five states
Honoring the Jon Huntsman Sr. political perspective: “I’m not a member of any party except the Cancer Party”

Mary Beckerle, a whitewater kayaker, has advice for all the folks in the cancer field: never catastrophize, never panic.

Trump administration broke law by canceling DEI research grants, GAO finds

The Government Accountability Office, an independent, non-partisan congressional watchdog agency, found that NIH violated the Impoundment Control Act of 1974 when it cancelled nearly 2,000 research grants in an effort to comply with several of President Donald Trump’s executive orders, including “Ending Radical And Wasteful Government DEI Programs And Preferencing” (The Cancer Letter, Jan 24, 2025).

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

EPCORE FL-1 phase III trial results show that subcutaneous epcoritamab in combination with rituximab and lenalidomide reduced the risk of disease progression or death by 79% for patients with relapsed/refractory follicular lymphoma.

August 08, 2025

Vol.51 No.31

City of Hope brings evidence-based approaches to integrative oncology

The landscape of cancer care is evolving rapidly, with growing recognition that optimal patient outcomes require a whole-person care approach that goes beyond cytotoxic and targeted therapies.

Six researchers awarded $5.3M for pancreatic cancer research by Stephenson Global

The Stephenson Global Pancreatic Cancer Research Institute and its partner, City of Hope, announced the six inaugural recipients of the Stephenson Scholar Grants, awarding $5.25 million to support high-impact research aimed at transforming the understanding, early detection, and treatment of pancreatic cancer (The Cancer Letter, Sept. 17, 2024).

July 25, 2025

Vol.51 No.29

In Brief

Dispatch Bio aims to deliver universal treatment across solid tumors with novel immunotherapy approach

Dispatch Bio, a company aiming to engineer a universal immunotherapy treatment across solid tumors, announced its official launch.

July 25, 2025

Vol.51 No.29

Diet influences survival after stage 3 colon cancer, Dana-Farber study finds

YOU MAY BE INTERESTED IN

The Directors: Mary Beckerle and Neli Ulrich on delivering cancer care across five states
Honoring the Jon Huntsman Sr. political perspective: “I’m not a member of any party except the Cancer Party”

Trump administration broke law by canceling DEI research grants, GAO finds

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

City of Hope brings evidence-based approaches to integrative oncology

Six researchers awarded $5.3M for pancreatic cancer research by Stephenson Global

Dispatch Bio aims to deliver universal treatment across solid tumors with novel immunotherapy approach

Renew today!

Subscriber content

Never miss an issue!

Login

Diet influences survival after stage 3 colon cancer, Dana-Farber study finds

YOU MAY BE INTERESTED IN

The Directors: Mary Beckerle and Neli Ulrich on delivering cancer care across five statesHonoring the Jon Huntsman Sr. political perspective: “I’m not a member of any party except the Cancer Party”

Trump administration broke law by canceling DEI research grants, GAO finds

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

City of Hope brings evidence-based approaches to integrative oncology

Six researchers awarded $5.3M for pancreatic cancer research by Stephenson Global

Dispatch Bio aims to deliver universal treatment across solid tumors with novel immunotherapy approach

Never miss an issue!

Login

The Directors: Mary Beckerle and Neli Ulrich on delivering cancer care across five states
Honoring the Jon Huntsman Sr. political perspective: “I’m not a member of any party except the Cancer Party”